(NASDAQ: BCYC) Bicycle Therapeutics's forecast annual revenue growth rate of -4.49% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 36.05%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.75%.
Bicycle Therapeutics's revenue in 2026 is $63,496,000.On average, 15 Wall Street analysts forecast BCYC's revenue for 2026 to be $1,635,467,568, with the lowest BCYC revenue forecast at $215,507,252, and the highest BCYC revenue forecast at $2,932,071,450. On average, 15 Wall Street analysts forecast BCYC's revenue for 2027 to be $909,500,639, with the lowest BCYC revenue forecast at $0, and the highest BCYC revenue forecast at $2,587,553,055.
In 2028, BCYC is forecast to generate $4,650,614,376 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $29,246,714,602.